Biosight Ltd. announced the initiation of a Phase II trial to evaluate aspacytarabine, Biosight’s proprietary antimetabolite, as a second line treatment for patients with relapsed or refractory myelodysplastic syndrome or acute myeloid leukemia.
[Biosight Ltd. (Globe Newswire)]
7992332
{7992332:nan}
apa
50
1
165751
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
